BiondVax Receives Green Light From Paul Ehrlich Institute For COVID-19 NanoAb Including First in human Phase 1/2a Clinical Trial

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing a pipeline of innovative NanoAbs for the prevention and treatment of infectious diseases and other illnesses,…

Continue Reading BiondVax Receives Green Light From Paul Ehrlich Institute For COVID-19 NanoAb Including First in human Phase 1/2a Clinical Trial